About Ying Huang
Ying Huang is a director at Quanta Therapeutics.
Ying Huang first appears on SEC filings in 2023.
Experience
This experience comes from Ying Huang's profile and from SEC filings. For roles taken from filings, the years are when the filings name Ying Huang in the role, so the role may have started earlier or lasted longer.
KT
K2 THERAPEUTICS Current
Chief Executive Officer
2026 – Present
AI
ADARx Pharmaceuticals Inc. Current
Board Member
2026 – Present
TB
Third Arc Bio Current
Board Member
2024 – Present
Quanta Therapeutics, Inc. Current
Director
2022 – Present · South San Francisco, CA
Develops cancer medicines for patients with RAS-driven cancers.
LB
Legend Biotech
Board Member
2019 – 2026
BL
Bank of America Merrill Lynch
Managing Director & Senior Analyst
2014 – 2019
BA
Barclays
Director
2011 – 2014
GC
Gleacher & Co.
Vice President and Senior Biotechnology Analyst
2010 – 2011
CS
Credit Suisse
Vice President
2008 – 2010
WS
Wachovia Securities
Associate Analyst
2007 – 2008
SC
Schering-Plough Corporation
Principal Scientist
1997 – 2007
Key Colleagues at Startups
The people Ying Huang works with at each company, as listed on that company's latest Form D.
Quanta Therapeutics, Inc. · Form D/A, Jun 24, 2026
MK
Maha Katabi
Director
PN
Perry Nisen
Chief Executive Officer and director
CP
Cameron Pitt
Chief Operating Officer and director
MF
Maria Fardis
Director
DM
Derek Metzger
Chief Strategy Officer
RJ
Rajul Jain
Director